よむ、つかう、まなぶ。
新型コロナウイルス感染症（COVID-19）診療の手引き・第 10.1 版 (19 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00111.html |
| 出典情報 | 新型コロナウイルス感染症（COVID-19）診療の手引き・第 10.1 版（4／23）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
●新型コロナウイルス感染症（COVID-19） 診療の手引き・第 10.1 版 ●２ 臨床像
3. 小児例の特徴
・国立感染症研究所．小児の重症度，小児における死亡例・新型コロナウイルス感染後の 20 歳未満の死亡例に関する積極的
疫学調査（第二報）．2022.12.28.
・日本小児科学会．小児への新型コロナワクチン令和 5 年度秋冬接種に対する考え方．2023.10.3.
・日本小児科学会予防接種・感染症対策委員会．新型コロナワクチン接種に関する，小児の基礎疾患の考え方および接種に
あたり考慮すべき小児の基礎疾患等．2022.8.17 改訂．
・Bellino S, et al. COVID-19 disease severity risk factors for pediatric patients in Italy. Pediatrics 2020.
・Katsuta T, et al. Acute and postacute clinical characteristics of Coronavirus disease 2019 in children in Japan.
Pediatr Infect Dis J 2022.
・United Nations Children’s Fund, The State of the World’s Children 2023: For every child, vaccination, UNICEF
Innocenti – Global office of research and foresight, Florence, April 2023.
4. 妊婦例の特徴
・出口雅士，山田秀人．日本における COVID-19 妊婦の現状 ～妊婦レジストリの解析結果（2022 年 5 月 5 日迄の登録症例）．
2022.6.7.
・日本産科婦人科学会周産期委員会・周産期における感染に関する小委員会．妊婦の新型コロナウイルスワクチン接種に関す
る WEB アンケート調査結果について．2022.1.12.
・Allotey J, et al. Clinical manifestations，risk factors，and maternal and perinatal outcomes of coronavirus disease
2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020.
・Engjom H, et al. Severe COVID-19 in pregnancy is almost exclusively limited to unvaccinated women-time for
policies to change. Lancet Reg Health Eur 2022．
・Goldshtein I, et al. Association of BNT162b2 COVID-19 vaccination during pregnancy with neonatal and early
infant outcomes. JAMA Pediatr 2022.
・Halasa NB, et al. Maternal vaccination and risk of hospitalization for Covid-19 among infants. N Engl J Med 2022.
・Hayakawa S, et al. Covid-19 pandemic and pregnancy. J Obstet Gynaecol Res 2020.
・Hayakawa S, et al. Anti-SARS-CoV-2 vaccination strategy for pregnant women in Japan. J Obstet Gynaecol Res
2021.
・Jaswa EG, et al. In utero exposure to maternal COVID-19 vaccination and offspring neurodevelopment at 12 and
18 months. JAMA pediatr 2024.
・Komine-Aizawa S, et al. Placental barrier against COVID-19. Placenta 2020.
・Shoji K, et al. Clinical characteristics and outcomes of COVID-19 in pregnant women: a propensity score matched
analysis of the data from the COVID-19 Registry Japan. Clin Infect Dis 2022.
・Villar J, et al. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern,
INTERCOVID-2022: a multinational, observational study. Lancet 2023.
・Wei SQ, et al. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ
2021.
・Zambrano LD, et al. Update: Characteristics of symptomatic women of reproductive age with laboratoryconfirmed SARS-CoV-2 infection by pregnancy status — United States，January 22–October 3, 2020. MMWR
2020．
5. 罹患後症状
・新型コロナウイルス感染症診療の手引き 別冊：罹患後症状のマネジメント 第 3 版．2023.10.20.
・Morioka S, et al. Post COVID-19 condition of the Omicron variant of SARS-CoV-2. J Infect Chemother 2022.
・Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat Med 2021.
・Soriano JB, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis
2022.
・Terai H, et al. Comprehensive analysis of long COVID in a Japanese nation wide prospective cohort study. Respir
Investig 2023.
【参考】COVID-19 ワクチン
・厚生労働省．新型コロナワクチンの副反応疑い報告について．
https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_hukuhannou-utagai-houkoku.html
・厚生労働省．オミクロン株対応１価ワクチン接種後の健康状況調査．
https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_kenkoujoukyoutyousa_xbb.html
・CDC. Early estimates of updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against
symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent
adults — Increasing community access to testing program, United States, September 2023–January 2024.
MMWR 2024.
・Hansen CH, et al. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in
Denmark: a national cohort study. Lancet 2024.
・van Werkhoven CH, et al. Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and
admission to intensive care, the Netherlands, 9 October to 5 December 2023. Eurosurveillance 2024.
◀︎ CONTENTS
19
3. 小児例の特徴
・国立感染症研究所．小児の重症度，小児における死亡例・新型コロナウイルス感染後の 20 歳未満の死亡例に関する積極的
疫学調査（第二報）．2022.12.28.
・日本小児科学会．小児への新型コロナワクチン令和 5 年度秋冬接種に対する考え方．2023.10.3.
・日本小児科学会予防接種・感染症対策委員会．新型コロナワクチン接種に関する，小児の基礎疾患の考え方および接種に
あたり考慮すべき小児の基礎疾患等．2022.8.17 改訂．
・Bellino S, et al. COVID-19 disease severity risk factors for pediatric patients in Italy. Pediatrics 2020.
・Katsuta T, et al. Acute and postacute clinical characteristics of Coronavirus disease 2019 in children in Japan.
Pediatr Infect Dis J 2022.
・United Nations Children’s Fund, The State of the World’s Children 2023: For every child, vaccination, UNICEF
Innocenti – Global office of research and foresight, Florence, April 2023.
4. 妊婦例の特徴
・出口雅士，山田秀人．日本における COVID-19 妊婦の現状 ～妊婦レジストリの解析結果（2022 年 5 月 5 日迄の登録症例）．
2022.6.7.
・日本産科婦人科学会周産期委員会・周産期における感染に関する小委員会．妊婦の新型コロナウイルスワクチン接種に関す
る WEB アンケート調査結果について．2022.1.12.
・Allotey J, et al. Clinical manifestations，risk factors，and maternal and perinatal outcomes of coronavirus disease
2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020.
・Engjom H, et al. Severe COVID-19 in pregnancy is almost exclusively limited to unvaccinated women-time for
policies to change. Lancet Reg Health Eur 2022．
・Goldshtein I, et al. Association of BNT162b2 COVID-19 vaccination during pregnancy with neonatal and early
infant outcomes. JAMA Pediatr 2022.
・Halasa NB, et al. Maternal vaccination and risk of hospitalization for Covid-19 among infants. N Engl J Med 2022.
・Hayakawa S, et al. Covid-19 pandemic and pregnancy. J Obstet Gynaecol Res 2020.
・Hayakawa S, et al. Anti-SARS-CoV-2 vaccination strategy for pregnant women in Japan. J Obstet Gynaecol Res
2021.
・Jaswa EG, et al. In utero exposure to maternal COVID-19 vaccination and offspring neurodevelopment at 12 and
18 months. JAMA pediatr 2024.
・Komine-Aizawa S, et al. Placental barrier against COVID-19. Placenta 2020.
・Shoji K, et al. Clinical characteristics and outcomes of COVID-19 in pregnant women: a propensity score matched
analysis of the data from the COVID-19 Registry Japan. Clin Infect Dis 2022.
・Villar J, et al. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern,
INTERCOVID-2022: a multinational, observational study. Lancet 2023.
・Wei SQ, et al. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ
2021.
・Zambrano LD, et al. Update: Characteristics of symptomatic women of reproductive age with laboratoryconfirmed SARS-CoV-2 infection by pregnancy status — United States，January 22–October 3, 2020. MMWR
2020．
5. 罹患後症状
・新型コロナウイルス感染症診療の手引き 別冊：罹患後症状のマネジメント 第 3 版．2023.10.20.
・Morioka S, et al. Post COVID-19 condition of the Omicron variant of SARS-CoV-2. J Infect Chemother 2022.
・Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat Med 2021.
・Soriano JB, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis
2022.
・Terai H, et al. Comprehensive analysis of long COVID in a Japanese nation wide prospective cohort study. Respir
Investig 2023.
【参考】COVID-19 ワクチン
・厚生労働省．新型コロナワクチンの副反応疑い報告について．
https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_hukuhannou-utagai-houkoku.html
・厚生労働省．オミクロン株対応１価ワクチン接種後の健康状況調査．
https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_kenkoujoukyoutyousa_xbb.html
・CDC. Early estimates of updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against
symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent
adults — Increasing community access to testing program, United States, September 2023–January 2024.
MMWR 2024.
・Hansen CH, et al. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in
Denmark: a national cohort study. Lancet 2024.
・van Werkhoven CH, et al. Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and
admission to intensive care, the Netherlands, 9 October to 5 December 2023. Eurosurveillance 2024.
◀︎ CONTENTS
19